References
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference (2002) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864–874
Meisner M (2002) Pathobiochemistry and clinical use of procalcitonin. Clin Chim Acta 323:17–29, Medline DOI 10.1016/S0009-8981(02)00101-8
Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C (1993) High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 341:515–518, Medline DOI 10.1016/0140-6736(93)90277-N
Oberhoffer M, Stonans I, Russwurm S, Stonane E, Vogelsang H, Junker U et al (1999) Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. J Lab Clin Med 134:49–55, Medline DOI 10.1016/S0022-2143(99)90053-7
Ho CL, Lasho TL, Butterfield JH, Tefferi A (2007) Global cytokine analysis in myeloproliferative disorders. Leuk Res 31:1389–1392, Medline DOI 10.1016/j.leukres.2006.12.024
Tefferi A (2000) Myelofibrosis with myeloid metaplasia. N Engl J Med 342:1255–1265, Medline DOI 10.1056/NEJM200004273421706
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stölzel, F., Babatz, J., Thiede, C. et al. Cyclic severe elevated procalcitonin serum levels in a patient with post polycythemic myelofibrosis carrying a V617F-JAK2 mutation. Ann Hematol 87, 1021–1022 (2008). https://doi.org/10.1007/s00277-008-0517-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-008-0517-5